Trials / Sponsors / Beijing Northland Biotech. Co., Ltd.

Beijing Northland Biotech. Co., Ltd.

Industry · 10 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Enrolling By Invitation	Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L) Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans	—	2025-06-30
Unknown	Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients Peripheral Artery Disease	Phase 3	2022-07-29
Completed	Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction Acute Myocardial Infarction	Phase 2	2022-07-15
Completed	Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction Acute Myocardial Infarction	Phase 2	2020-11-23
Completed	Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2) Arterial Occlusive Disease, Ischemia, Ulcers	Phase 3	2019-08-28
Completed	Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) Arterial Occlusive Disease, Ischemia, Ulcers	Phase 3	2019-08-02
Completed	A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers Healthy	Phase 1	2018-07-30
Completed	A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers Healthy	Phase 1	2017-07-17
Completed	A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 Chemotherapy-induced Thrombocytopenia	Phase 3	2015-03-01
Completed	Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia Arterial Occlusive Disease, Ulcers, Ischemia	Phase 2	2012-03-01